Research Overview
A peptide written in mitochondrial DNA
MOTS-c was identified through analysis of short open reading frames in the mitochondrial genome, specifically within the 12S rRNA gene. That origin sets it apart from nuclear-encoded signalling peptides and places it in the mitochondrial-derived peptide family with humanin and the small humanin-like peptides. Its discovery supported the broader idea that mitochondria communicate with the nucleus through peptide signals rather than only through metabolites and redox state.
Reported mechanisms
Published cell and rodent studies have described several converging observations:
- Activation of AMPK, the principal cellular energy sensor, with downstream metabolic effects
- Interference with the folate-dependent one-carbon cycle, altering purine biosynthesis intermediates such as AICAR
- Nuclear translocation under metabolic stress, with binding at antioxidant-response elements
- Changes in glucose uptake and insulin sensitivity measures in diet-induced obese mice
- Declining endogenous levels with age in some tissue and plasma measurements
Why an oral format is studied
A 16-residue peptide entering the stomach faces acidic hydrolysis, pepsin, pancreatic proteases and brush-border peptidases before it can reach an enterocyte, and paracellular transport of a 2.1 kDa hydrophilic molecule is limited. Oral bioavailability for unmodified peptides of this class is generally low. That makes the oral capsule a legitimate research article for questions about gastrointestinal degradation kinetics, enteric or permeation-enhancing formulation strategies, and local action on gut tissue, rather than a substitute route for systemic exposure.
